ENvue Medical, Inc. (FEED): Nasdaq/NYSE listing notice — NanoVibronix receives Nasdaq delisting notice for bid price below $1.00

ENvue Medical, Inc.

Nasdaq letter on April 10, 2024: common stock failed $1.00 minimum bid for 30 consecutive business days.
Compliance period of 180 calendar days until October 7, 2024 to regain listing requirement.
To cure, closing bid price must be $1.00 or more for at least 10 consecutive business days.
If not cured, may be eligible for additional 180-day period if other listing standards are met.
No immediate impact on trading; common stock continues to trade on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ENvue Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 10, 2024, NanoVibronix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between February 27, 2024, to April 9, 2024, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until Oc

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ENvue Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-014611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.